Body Brain Trainer (BBT)
Motion capture video game integrating cognitive and physical training for attention and working memory
Software · EmbeddedCompany source
Company profile
About Akili
Akili Interactive is pioneering a new class of digital medicines that combine world-class neuroscience with video game technology to treat cognitive impairments. The company has developed proprietary technology platforms that deliver specific sensory stimuli and motor challenges designed to target neural systems in the brain related to attentional control. Their flagship product, EndeavorRx, is the first and only FDA-approved prescription video game treatment for children aged 8-17 with primarily inattentive or combined-type ADHD. Building on this technology, Akili launched EndeavorOTC, an over-the-counter treatment for adults with ADHD available without prescription. Both products are built on the company's patented Selective Stimulus Management Engine (SSME) technology, which uses adaptive algorithms to personalize treatment difficulty for each individual patient. The technology has been rigorously evaluated across more than 30 clinical trials, including the STARS-ADHD study published in The Lancet Digital Health. Akili's approach represents a fundamental shift in how medicine is designed, delivered, and experienced—creating treatments that are not just effective, but engaging and enjoyable. The company continues to research applications of their technology across multiple cognitive conditions beyond ADHD, including autism spectrum disorder and sensory processing dysfunction.
Company description Akili official website
Primary marketMental Health & Digital Therapeutics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Akili?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- ADHD (children and adults)
- Autism Spectrum Disorder with co-occurring ADHD symptoms
- COVID Brain Fog
- General cognitive impairments
- Sensory Processing Dysfunction
Who it serves
- Consumers (patients/families)
- Healthcare providers (prescribers)
- Payers
Deployment & integration
Cloud Saas · Embedded deployment with recorded integration context.
Geographic context
MarketsEurope · United States
Company sourceOfficial website
Company milestones
Platform expansion
Launch of EndeavorOTC for adults with ADHD (over-the-counter, available on App Store and Google Play); FDA authorization for EndeavorRx as first prescription video game treatment; CE Mark certification in Europe; Publication of STARS-ADHD trial in The Lancet Digital Health; 2023 ADHD in Workplace Report
Partnerships
Recorded partners
No partners are currently listed.
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
EndeavorOTC
Game-based treatment clinically proven to improve focus and attention in adults with ADHD, available OTC
Software · Cloud SaaSCompany source
EndeavorRx
First FDA-approved prescription video game treatment for children with ADHD
Software · Cloud SaaSCompany source
Selective Stimulus Management Engine (SSME)
Proprietary technology platform targeting neural systems involved in attentional control
Platform · EmbeddedCompany source
Spatial Navigation (SNAV) Engine
Technology targeting neural systems involved in spatial navigation, memory, and planning
Platform · EmbeddedCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Evaluating changes in recovery in people living with severe and persistent mental illness after psychiatric rehabilitation services at Moi Teaching and Referral Hospital, Eldoret, Kenya.Psychiatric rehabilitation journal · Mar 1, 2025
Behavioral characteristics of toddlers later identified with an autism diagnosis, ADHD symptoms, or combined autism and ADHD symptoms.Journal of child psychology and psychiatry, and allied disciplines · Feb 1, 2025
A digital intervention for cognitive deficits following COVID-19: a randomized clinical trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · Dec 1, 2024
Real-time cognitive performance metrics derived from a digital therapeutic for inattention predict ADHD-related clinical outcomes: Replication across three independent trials of AKL-T01.Translational psychiatry · Aug 11, 2024
Brief Report: Relationships Between Caregiver-Reported Externalizing and Internalizing Behaviors and the Modified Checklist for Autism in Toddlers.Journal of autism and developmental disorders · Jul 12, 2024
Two single arm trials of AKL-T01, a digital therapeutic for adolescents and adults with ADHD.Npj mental health research · Jun 19, 2024
Clinical validation
Clinical-trial records
Cognitive Control Targets for the Treatment of Obsessive Compulsive Disorder in Young ChildrenNCT06102941 · Mentioned · RECRUITING
Cognitive Training in Survivors of Covid-19: A Randomized TrialNCT04956887 · Mentioned · COMPLETED
Feasibility and Efficacy of Attentional-Control Training in Sickle Cell DiseaseNCT05099874 · Mentioned · RECRUITING
EndeavorOTC® Research Study in College StudentsNCT06376032 · Sponsor · UNKNOWN
EndeavorOTC™ Prospective Product RegistryNCT06109051 · Sponsor · ACTIVE NOT RECRUITING
EndeavorRx® Prospective Product Registry ("Expedition EndeavorRx")NCT05991167 · Sponsor · UNKNOWN
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Improved attention function
Children with ADHD in STARS-ADHD trial
Improved focus and attention
Adults with ADHD using EndeavorOTC
Enhanced cognitive control
Children with ASD and co-occurring ADHD symptoms
Adolescent ADHD Pivotal Trial
Pivotal trial of EndeavorRx in adolescents with ADHD
Showed robust improvements in attention and broader clinical outcomes
Lupus (SLE) Clinical Study
Investigator-initiated study in patients with Systemic Lupus Erythematosus
Demonstrated improved executive function in patients with SLE, published in The Journal Lupus
Major Depressive Disorder Clinical Study
Study of AKL-T03 combined with antidepressant medication in adults with major depressive disorder
Improved cognition in adults with MDD when combined with antidepressant medication, published in American Journal of Psychiatry
Shionogi Phase 2 Study Japan
Phase 2 study evaluating Akili's digital treatment in Japanese children with ADHD
Digital treatment was well-received and improved inattention symptoms in children with ADHD
Weill Cornell Medicine, NewYork-Presbyterian Hospital and Vanderbilt University Medical Center
Collaboration to study digital therapeutic AKL-T01 as treatment for COVID Brain Fog
STARS-ADHD Clinical Trial
Randomized controlled trial evaluating EndeavorRx for pediatric ADHD treatment
Published in The Lancet Digital Health demonstrating improved attention function in children with ADHD
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Scott Kollins
Chief Medical Officer
Matt Franklin
President and Chief Operating Officer
06 · Company updates
Updates from Akili
Recent articles published on Akili's official website.
Pivotal Trial of EndeavorRx® in Adolescents with ADHD Shows Robust Improvements in Attention and Broader Clinical Outcomes
Read on AkiliAkili Announces ADHD Expert Dr. Scott Kollins to Join as Chief Medical Officer
Read on AkiliFinancial Industry Veteran Mary Hentges Joins Akili’s Board of Directors
Read on Akili07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Mental Health & Digital Therapeutics
Companies providing AI-powered mental health support, therapy platforms, mental wellness tracking, psychiatric care, digital therapeutics for mental health conditions, or AI-driven mental health screening and monitoring. Includes XR-based therapy, AI mental health screening infrastructure, and platforms supporting behavioral health for individuals and health systems.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.